Omeros(US:OMER)2025-03-31 20:25Financial Performance - Net loss for Q4 2024 was $31.4 million, or $0.54 per share, compared to a net loss of $32.2 million, or $0.56 per share in Q3 2024[3]. - For the year ended December 31, 2024, net loss was $156.8 million, or $2.70 per share, compared to a net loss of $117.8 million, or $1.88 per share in the prior year[8]. - The company reported a net loss of $31.4 million for Q4 2024, compared to a net loss of $9.1 million in Q4 2023[21]. - The accumulated deficit increased to $910.3 million as of December 31, 2024, from $753.5 million a year earlier[23]. Cash and Investments - Cash and short-term investments available for operations and debt servicing as of December 31, 2024, were $90.1 million, a decrease of $81.7 million from December 31, 2023[9]. - Cash and cash equivalents were $3.4 million as of December 31, 2024, compared to $7.1 million at the end of 2023[23]. Revenue and Royalties - OMIDRIA royalties earned in Q4 2024 were $10.1 million on U.S. net sales of $33.6 million, compared to $9.3 million on U.S. net sales of $31.0 million in Q3 2024[10]. - Net income from discontinued operations was $5.2 million for Q4 2024, compared to $4.9 million in Q3 2024[12]. Operating Expenses - Total operating expenses for Q4 2024 were $35.7 million, slightly up from $35.4 million in Q3 2024[11]. - Significant cost outlays during 2024 totaled $42.7 million, including $21.7 million for repurchasing convertible senior notes and $19.1 million for narsoplimab drug substance delivery[9]. - Research and development expenses for Q4 2024 were $23.3 million, down from $28.9 million in Q4 2023[21]. - Selling, general and administrative expenses increased to $12.3 million in Q4 2024 from $10.9 million in Q4 2023[21]. - Interest expense decreased to $3.2 million in Q4 2024 from $4.1 million in the prior quarter, primarily due to the remeasurement of the OMIDRIA royalty obligation[11]. Drug Development and Regulatory Updates - The biologics license application (BLA) for narsoplimab was resubmitted to the FDA in March 2025, with a target action date of September 2025[4]. - The European marketing authorization application (MAA) for narsoplimab is expected to be submitted in the first half of 2025[3]. - The Phase 3 program for zaltenibart in treating paroxysmal nocturnal hemoglobinuria (PNH) has been initiated, including two studies targeting different patient populations[5]. - NIDA confirmed funding of $4.02 million for the OMS527 program, aimed at treating cocaine use disorder, starting April 1, 2025[6]. - Narsoplimab demonstrated a hazard ratio of 0.32 in overall survival compared to an external control population of TA-TMA patients, indicating significant clinical efficacy[4]. - Omeros' lead drug candidate, narsoplimab, is pending FDA review for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy[16]. Assets - Total assets decreased to $277.1 million as of December 31, 2024, down from $378.3 million a year earlier[23].